{"id":"W4391694006","doi":"10.1200/jco.23.01134","title":"ONC201 (Dordaviprone) in Recurrent H3 K27M–Mutant Diffuse Midline Glioma","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"Helsinn Therapeutics; Regeneron Pharmaceuticals; Springworks Therapeutics; Novocure; Celgene; Bristol-Myers Squibb; American Society of Clinical Oncology; Helsinn; National Cancer Institute; Kaiser Permanente; Children's National Hospital; American Academy of Neurology; Ono Pharmaceutical","keywords":"Medicine; Glioma; Progressive disease; Clinical endpoint; Radiation therapy; Surgery; Internal medicine; Gastroenterology; Urology; Nuclear medicine; Chemotherapy; Randomized controlled trial; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007840953,0.0002639536,0.0006480365,0.0002416193,0.00008357538,0.0003506593,0.000261427,0.0001764639,0.0006769436],"category_scores_gemma":[0.0007246227,0.0001048147,0.0004953539,0.0002708949,0.0002025753,0.0002305845,0.0001873378,0.0003616899,0.0001070634],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006917749,"about_ca_system_score_gemma":0.000644804,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007344728,"about_ca_topic_score_gemma":0.003193242,"domain_scores_codex":[0.9997171,0.0001076452,0.00003233871,0.00004687429,0.00005566799,0.00004040369],"domain_scores_gemma":[0.9996209,0.00007355279,0.0001712061,0.00002171556,0.00002878636,0.00008372144],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2359764,0.005523033,0.1721717,0.00225331,0.00409792,0.0005425221,0.0003795925,0.006004056,0.06087948,0.000428103,0.001596278,0.5101475],"study_design_scores_gemma":[0.06043996,0.4841833,0.396937,0.0002845637,0.005726208,0.003176099,0.0004783018,0.007417062,0.02788057,0.0004544879,0.01294651,0.00007605243],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9969111,0.002282217,0.0001262468,0.0000490908,0.000007247595,0.0001006752,0.0001295252,0.0000150609,0.0003788106],"genre_scores_gemma":[0.9986355,0.0007783275,0.0002267331,0.00003500401,0.000008121553,0.00003697496,0.0001528571,0.000002119392,0.0001244172],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0007840953,"threshold_uncertainty_score":0.005019188,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.134791375236248,"score_gpt":0.4833792657145425,"score_spread":0.3485878904782945,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}